The diffusion-weighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: a pilot study
- 5 August 2010
- journal article
- hepatobiliary pancreas
- Published by Springer Science and Business Media LLC in European Radiology
- Vol. 21 (2), 281-290
- https://doi.org/10.1007/s00330-010-1914-4
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenibBMC Cancer, 2009
- Biomarkers of response and resistance to antiangiogenic therapyNature Reviews Clinical Oncology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal Of Cancer, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Clinical significance of α‐fetoprotein: involvement in proliferation, angiogenesis, and apoptosis of hepatocellular carcinomaJournal of Gastroenterology and Hepatology, 2008
- Diffusion-weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis CHepatology, 2007
- Diffusion-Weighted MRI in the Body: Applications and Challenges in OncologyAmerican Journal of Roentgenology, 2007
- Management of hepatocellular carcinomaHepatology, 2005
- Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic TherapyScience, 2005
- Angiogenesis and hepatocellular carcinomaJournal of Hepatology, 2004